Blockade of the pro-fibrotic reaction mediated by the miR-143/-145 cluster enhances the responses to targeted therapy in melanoma.

导出 OA

翻译打印收藏纠错

作者： Serena,Diazzi ^[1] ; Alberto,Baeri ^[2] ; Julien,Fassy ^[3] ; Margaux,Lecacheur ^[2] ; Oskar,Marin-Bejar ^[2] ; Christophe A,Girard ^[1] ; Lauren,Lefevre ^[3] ; Caroline,Lacoux ^[4] ; Marie,Irondelle ^[5] ; Carine,Mounier ^[1] ; Marin,Truchi ^[3] ; Marie,Couralet ^[1] ; Mickael,Ohanna ^[3] ; Alexandrine,Carminati ^[2] ; Ilona,Berestjuk ^[1] ; Frederic,Larbret ^[2] ; David,Gilot ^[6] ; Georges,Vassaux ^[2] ; Jean-Christophe,Marine ^[2] ; Marcel,Deckert ^[1] ; Bernard,Mari ^[3] ; Sophie,Tartare-Deckert ^[1]

作者单位： Université Côte d'Azur, INSERM, C3M, Nice, France. ^[1] Université Côte d'Azur, CNRS, Institut de Pharmacologie Moléculaire et Cellulaire (IPMC), Sophia Antipolis, France. ^[2] Equipe labellisée Ligue Contre le Cancer, Nice, France. ^[3] Laboratory For Molecular Cancer Biology, VIB Center for Cancer Biology, VIB, Leuven, Belgium. ^[4] Department of Oncology, KU Leuven, Leuven, Belgium. ^[5] CYU Université, ERRMECe (EA1391), Neuville-sur-Oise, France. ^[6] INSERM U1242, University of Rennes, Rennes, France. ^[7] FHU-OncoAge, Nice, France. ^[8]

关键词 MAPK inhibitors fibrosis melanoma microRNA nintedanib